NCT06423001View on ClinicalTrials.gov

Efficacy and Safety of Oral Administration of Postibiotic by FOS Fermentation From Lactobacillus Paracasei in the Treatment of Irritable Bowel Syndrome.

NANot yet recruitingINTERVENTIONAL
Enrollment

36

Participants

Timeline

Start Date

June 15, 2024

Primary Completion Date

May 15, 2025

Study Completion Date

May 15, 2026

Conditions
IBS - Irritable Bowel Syndrome
Interventions
DIETARY_SUPPLEMENT

PostbiotiX Slowing 4 g sachets PostbiotiX Slowing is a food supplement based on Fermented FOS from Lactobacillus paracasei CNCM I-5220.

Each patient will be supplied with the investigational product at Visit 0, PostibiotiX Slowing and at visit 3, based on the outcome of the randomization at V0 (Sequence AB, PostbiotiX Slowing/Placebo; Sequence BA, Placebo/PostbiotiX Slowing).

Trial Locations (1)

20089

Department of Gastroenterology, Humanitas Research Hospital, Rozzano

All Listed Sponsors
lead

Istituto Clinico Humanitas

OTHER

NCT06423001 - Efficacy and Safety of Oral Administration of Postibiotic by FOS Fermentation From Lactobacillus Paracasei in the Treatment of Irritable Bowel Syndrome. | Biotech Hunter | Biotech Hunter